News

Bayer CropScience signs R&D pact
Enlarge image

ResearchGermany

Bayer CropScience signs R&D pact

06.09.2012 - Bayer CropScience and US firm Mendel Biotechnology will co-develop a herbicide resistance breaking technology.

The focus of the new multi-year collaboration with the US plant genomics specialist is to jointly identify herbicides with novel modes of action, because many weeds have developed resistance to multiple herbicide classes. Under the terms of the agreement, the global No. 2 in herbicides, will bring in its expertise in herbicide research and development. Mendel will contribute its knowledge of plant genetic regulatory networks (PGRNs) – especially its know-how on regulatory transcription factors that can contribute to herbicide resistance. 
  

“We believe that this collaboration will help us continue our significant contributions in agricultural chemistry“, quoted Dr. C. David Nicholson, Global Head of Research & Development at Bayer CropScience. He added he hoped the combined know-how would  help growers to tackle weed resistance issues and to protect their crops.”



Mendel has already partnered with the Germans in identifying chemicals that modulate the plant’s stress response signalling networks. The company has extensive knowledge on the set of transcription factors and regulatory networks in different plants identified by 1st PGRN platform and hold patents on cold and drought resistance

http://www.european-biotechnology-news.com/news/news/2012-03/bayer-cropscience-signs-rd-partnership.html

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • FORMYCON24.58 EUR6.18%
  • CYTOS1.45 CHF3.57%

FLOP

  • MEDIGENE10.52 EUR-9.70%
  • BIOFRONTERA2.53 EUR-3.44%
  • 4SC1.25 EUR-2.34%

TOP

  • CYTOS1.45 CHF326.5%
  • MEDIGENE10.52 EUR147.5%
  • 4SC1.25 EUR60.3%

FLOP

  • MORPHOSYS56.55 EUR-24.4%
  • WILEX3.00 EUR-12.5%
  • BASILEA108.00 CHF-11.6%

TOP

  • SANTHERA92.40 CHF2269.2%
  • WILEX3.00 EUR400.0%
  • FORMYCON24.58 EUR251.1%

FLOP

  • CYTOS1.45 CHF-51.3%
  • MOLOGEN5.81 EUR-48.7%
  • PAION2.34 EUR-29.9%

No liability assumed, Date: 29.03.2015